Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics seeks $75 million in an IPO, testing market appetite for early-stage biotech.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Scribe Therapeutics, an Alameda-based company specializing in gene-editing and cardiovascular disease treatments, has filed for a proposed initial public offering on the Nasdaq. The company aims to raise $75 million through the listing, with notable existing stockholders including Eli Lilly.
Coverage from Renaissance Capital, The Business Journals, and Investing.com highlights the firm's focus on cholesterol-fighting treatments and gene-editing technology. Endpoints News frames the filing as a significant test of public investor sentiment toward earlier-stage biotech companies.
Future coverage is expected to clarify the proposed share price range and the specific use of proceeds for the $75 million offering. Reports do not yet specify the ticker symbol or the timing of the IPO pricing.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 114d ago.
Quick answers
What is Scribe Therapeutics?
It is an Alameda-based biotech company focused on gene-editing and treatments for cardiovascular diseases and high cholesterol.
How much does the company plan to raise?
The company filed for a proposed $75 million IPO.
Who backs Scribe Therapeutics?
Current stockholders include Eli Lilly, though a full list of investors is not specified in the coverage.
Coverage (5)
- SCTX IPO News - Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO renaissancecapital.com · 117d ago
- Meet the gene-editing, cholesterol-fighting Alameda company looking for IPO riches The Business Journals · 117d ago
- Scribe Therapeutics files for proposed Nasdaq IPO By Investing.com Investing.com South Africa · 117d ago
- Scribe Therapeutics Stockholders Include Eli Lilly Moomoo · 117d ago
- Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs Endpoints News · 117d ago
Topics
Related trends
As AI becomes more fractured, one names stands out: AMD
Investors and analysts are focusing on AMD as a standout name amidst a fracturing AI landscape ahead of the company's Q3 financial results.
VCs will make billions on Anthropic’s IPO, but Amazon is set to make much (much) more
Venture capitalists stand to gain billions from Anthropic's IPO, but Amazon is positioned for even larger returns according to recent reporting.
Anthropic IPO warns its AI could blackmail people, become sentient, end humanity
Anthropic's recent transition to a public company raises critical questions regarding its internal governance and leadership structure.
Ferring Signs $1.4 Billion Deal to Buy Gameto Fertility Startup
Ferring Pharmaceuticals has reached a deal to acquire Austin-based fertility biotech startup Gameto for up to $1.4 billion.
Mo. Attorney General sends prescription manufacturer Eli Lilly cease-and-desist over drug price policy
The Missouri Attorney General has issued a cease-and-desist letter to Eli Lilly over drug pricing policies and 340B discount requirements.
Why Anthropic's IPO contrasts the 'cult of Elon Musk' at SpaceX and Tesla
Anthropic's IPO filing reveals a strategic pivot toward biotech and hardware efficiency that challenges the industry's established power dynamics.